-+ 0.00%
-+ 0.00%
-+ 0.00%

THE EUROPEAN MEDICINES AGENCY ACCEPTS TEVA’S MARKETING AUTHORIZATION APPLICATION FOR OLANZAPINE LONG-ACTING INJECTABLE (TEV-‘749) FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS

Reuters·05/21/2026 16:30:00

Please log in to view news